c-Fms
CSF-1 receptor; colony stimulating factor 1 receptor; CSF-1R; CSF1R
c-FMS (CSF1R, CSF-1R) is a receptor protein-tyrosine kinase of the platelet-derived growth factor receptor (PDGFR) family. c-FMS is the cell surface receptor for IL-34 and CSF1. c-FMS has important roles in haematopoiesis, regulation of proliferation, cell survival and maturation of microglia and monocytes, as well as in controlling the overall immune response.
c-FMS is specifically expressed in osteoclasts and myelomonocytic-lineage cells, such as monocytes and macrophages, and the activation of c-FMS signaling promotes the proliferation or differentiation of these cells. It also promotes the production of inflammatory mediators, such as tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL6).
All Product Categories
-
c-Fms Related Products (141)
Related Products (141)
-
Recombinant Proteins (23)
-
Antibodies (8)
-
GENZ-882706(Raceme)
0 ImagesCat. No.: HY-101526RCAS No.: 2070861-46-8Synonyms: GENZ-882706 racemateGENZ-882706(Raceme) is the racemate of GENZ-882706. GENZ-882706(Raceme) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
Adrixetinib TFA
0 ImagesCat. No.: HY-152830APurity: 99.82%Synonyms: Q702 TFAAdrixetinib (Q702) TFA is an orally active triple inhibitor against CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib TFA acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib TFA increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib TFA upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib TFA shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib TFA is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma.
-
Eflapegrastim
0 ImagesCat. No.: HY-P99913CAS No.: 1384099-30-2Eflapegrastim is a composite protein consisting of a genetically modified granulocyte-colony stimulating factor (GCSF) molecule linked via a chemical bond to an IgG4 Fc fragment (LAPS-carrier). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia.
-
c-Fms-IN-2
0 Imagesc-Fms-IN-2 is a FMS kinase inhibitor with an IC50 of 0.024 μM.
-
Pazopanib-13C,d3 hydrochloride
0 ImagesCat. No.: HY-12009SCAS No.: 1261398-44-0Synonyms: GW786034-13C,d3 hydrochloride
-
GENZ-882706
0 ImagesCat. No.: HY-101526CAS No.: 2070864-35-4Synonyms: RA03546849GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor extracted from patent WO 2017015267A1.
-
c-Fms-IN-3
0 Imagesc-Fms-IN-3 is an orally active c-Fms (CSF1R) kinase inhibitor (IC50 = 0. 8 nM). c-Fms-IN-3 inhibits CSF1R kinase activity and reduces macrophage populations. c-Fms-IN-3 reduces bone erosion, pannus invasion, cartilage damage, and inflammation in collagen (HY-NP003)-induced arthritis mouse model. c-Fms-IN-3 is useful for arthritis research.
-
BPR1R024 mesylate
0 ImagesCat. No.: HY-132935ACAS No.: 2763365-40-6BPR1R024 mesylate is an orally active and selective colony-stimulating factor-1 receptor (CSF1R) inhibitor. BPR1R024 mesylate is the equivalent of BPR1R024 (HY-132935). BPR1R024 has potent CSF1R inhibition activity with an IC50 value of 0.53 nM. BPR1R024 can be used for the research of immuno-oncology.
-
c-Fms-IN-13
0 Imagesc-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor with an IC50 value of 17 nM. c-Fms-IN-13 can be used as an anti-inflammatory agent.
-
GW2580-d6
0 ImagesGW2580-d6 is the deuterium labeled GW2580. GW2580 is an orally bioavailable and selective inhibitor of c-Fms kinase which completely inhibits human cFMS kinase in vitro at 0.06 μM. GW2580 acts as a competitive inhibitor of ATP binding to the cFMS kinase and inhibits colony-stimulating-factor-1 signaling.
-
BRD4-BD1/2-IN-3
0 ImagesBRD4-BD1/2-IN-3 (Compound B6) is a selective BRD4 BD2 inhibitor with an IC50 of 0.41 nM for BRD4 BD2 over BRD4 BD1. BRD4-BD1/2-IN-3 significantly inhibits the LPS (HY-D1056)-induced expression of IL-6. BRD4-BD1/2-IN-3 shows anti-inflammatory activities by modulating the TNF and NF-κB signaling pathway. BRD4-BD1/2-IN-3 can be used for inflammatory diseases research.
-
JNJ-28312141
0 ImagesCat. No.: HY-13496CAS No.: 885692-52-4JNJ-28312141 is an inhibitor for colony-stimulating factor-1 receptor (CSF-1R or FMS), with an IC50 of 0.69 nM. JNJ-28312141 inhibits proliferation of BDBM, MV-4-11, M-o7e, TF-1 with an IC50s of 2.6, 21, 41 and 150 nM, respectively. JNJ-28312141 exhibits anti-inflammatory activity in mouse arthritis model.
-
Segigratinib
0 ImagesCat. No.: HY-159503CAS No.: 1882873-93-9Synonyms: 3D185 free base; HH185 free baseSegigratinib is a fibroblast growth factor receptor tyrosine kinase inhibitor, with antineoplastic effect.
-
JMC14
0 ImagesCat. No.: HY-174366CAS No.: 2256080-83-6JMC14 is a selective and orally active PI3Kδ and CSF1R inhibitor with IC50 values of 12 nM and 143 nM, respectively. JMC14 preferentially inhibits PI3Kδ-mediated signaling at the cellular level. JMC14 demonstrates potent antitumor activity against B-cell lymphomas and triple-negative breast cancer (TNBC) in both in vitro and vivo studies. JMC14 can be used for the study of antitumor immunity.
-
Sotuletinib dihydrochloride
0 ImagesCat. No.: HY-12768BCAS No.: 2222138-40-9Synonyms: BLZ945 dihydrochlorideSotuletinib (BLZ945) dihydrochloride is a potent, selective, orally active and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs. Sotuletinib dihydrochloride can be used for microglia depletion, and for tumor and CNS-related disease research.
-
Axl/Mer/CSF1R-IN-2
0 ImagesCat. No.: HY-153277CAS No.: 2394874-63-4
-
IACS-9439
0 ImagesCat. No.: HY-153243CAS No.: 2231259-36-0IACS-9439 is a potent, selective, and orally active CSF1R inhibitor with a Ki value of 1 nM inhibitor. IACS-9439 can be used for advanced solid tumors research.
-
ABD-295
0 ImagesCat. No.: HY-111248CAS No.: 871113-99-4ABD-295, a biphenylsulfide derivative, is an antiresorptive agent, osteoclast inhibitor. ABD-295 has potent inhibitory effects on osteoclastic bone resorption in vitro. ABD-295 prevents ovariectomy-induced bone loss in vivo[1].
-
CSF1R-IN-5
0 ImagesCat. No.: HY-144041CAS No.: 2716184-93-7CSF1R-IN-5 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-5 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-5 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 11).
